In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Prothena (PRTA – Research Report), with a price target of $36.00. The company’s shares closed yesterday at $32.93.
According to TipRanks, Abrahams is a 5-star analyst with an average return of 9.2% and a 50.20% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, BioCryst, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Prothena is a Strong Buy with an average price target of $74.29.
See the top stocks recommended by analysts >>
Based on Prothena’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $84.87 million and a net profit of $21.91 million. In comparison, last year the company earned a revenue of $1.52 million and had a GAAP net loss of $45.76 million
Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena (PRTA) Company Description:
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More on PRTA:
- Prothena put volume heavy and directionally bearish
- Prothena remains on track with partnered programs, provides updates
- The biotech stocks to own in 2024, according to Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
